BeOne Medicines, USA
ABOUT US
We’re building the world’s leading oncology company – driven by scientific excellence and exceptional speed – to reach more patients than ever before.
Together, we are how the world stops cancer.
Patients First
Stand up for patients everywhere.
Driving Excellence
Make a lasting impact in the world.
Bold Ingenuity
Challenge the status quo to deliver science once thought to be impossible.
Collaborative Spirit
Foster superior, non-hierarchical teamwork.
55 Cambridge Pkwy suite 700w
Cambridge, MA 02142
(615) 414-6211
beigene.com
PRIMARY CONTACTS
Eric Kite
National Account Director
eric.kite@beonemed.com
Hoa Pham
Senior Director, Medical Value & Outcomes
hoa.pham@beigene.com
PRODUCTS OR SERVICES
Targeting Blood Cancers
Blood cancer is a key focus area for BeOne Medicines, particularly b-cell malignancies.
New Approaches to Treatment
There are many ways to treat blood cancer, and new options are being studied all the time. Treatments may depend on the type of blood cancer, the aggressiveness of the disease, the overall health of the patient, and many more factors. These may include surgery, chemotherapy, radiation, targeted therapy, immunotherapy, a stem cell transplant or a combination of these approaches.5
Today, BeOne is working to develop potential first-in-class and best-in-class therapies to address B-cell malignancies, including chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL). Our research areas include:
- Targeted therapies, which can target specific proteins within B-cell malignancies to stop cancer growth. This includes:
- The cornerstone of our hematology franchise – our Bruton’s tyrosine kinase (BTK) inhibitor, which can treat B-cell malignancies by shutting down (or inhibiting) proteins within cancerous B cells.
- Our late-stage B-cell lymphoma 2 (BCL2) inhibitor, which is part of a group of drugs called BH3 mimetics, which mimic natural cell death signals.
- Protein degraders from our Chimeric Degradation Activation Compound (CDAC) platform, which use the cell’s natural ability to dispose of unwanted cells like cancer cells. By harnessing this approach, therapies like protein degraders target cancer cell proteins to signal for them to be destroyed.
Solid Tumors
At BeOne Medicines our goal is to develop innovative medicines to address the unmet needs of large and broad populations worldwide. One of our key areas of research is solid tumor oncology.
Each year, more than 20 million new cancer cases are diagnosed worldwide;1 solid tumor cancers constitute more than 90% of all new cases of cancer.2 Solid tumors form when normal cells mutate and start growing uncontrollably, ignoring the body’s signals to stop dividing or die.2 As the tumor grows, it creates its own blood supply for nutrients, may eventually spread to other parts of the body and can find ways to avoid detection by the immune system, making it harder to eliminate.2
BeOne is working to develop potential first-in-class and best-in-class therapies for some of the most challenging solid tumor cancers, taking a disease-focused approach.
Our areas of focus include Gastrointestinal cancers/Lung cancers/Breast and gynecologic cancers and other cancers